Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen is a leading provider of peripheral nerve repair technologies, with a differentiated product portfolio and steady revenue growth. The company's strong financial profile, including positive cash flow and a healthy cash position, positions it for future success and growth through investments in infrastructure and potential acquisitions. With FDA approval for its key product until 2037 and a strong management team, AXGN is well-positioned to continue its growth trajectory in the Medtech industry.

Bears say

Axogen is a MedTech company with products focused on peripheral nerve regeneration and repair, but its recent stock price surge (+238% vs. IHI -10% and IBB +58%) is not indicative of the company's long-term growth potential. While it has seen strong growth in its flagship product Avance, it is still early in its growth cycle and has a long way to go before it reaches its full potential. Additionally, the company's recent initiatives to increase its sales force and expand its product offerings may lead to further margin compression in the near term. Overall, while Axogen has potential for long-term growth, it may not yet be a strong investment opportunity at its current valuation.

AxoGen (AXGN) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Strong Buy based on their latest research and market trends.

According to 9 analysts, AxoGen (AXGN) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.